Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Lymphoma 138Lymphoma, Non-Hodgkin 84Lymphoma, Large B-Cell, Diffuse 83Small Cell Lung Carcinoma 78Hodgkin Disease 61Precursor Cell Lymphoblastic Leukemia-Lymphoma 59Leukemia 57Burkitt Lymphoma 56Lung Neoplasms 49Lymphoma, Follicular 47Lymphoma, Mantle-Cell 44Leukemia, Myeloid, Acute 41Lymphoma, Large-Cell, Immunoblastic 40Multiple Myeloma 33Leukemia, Lymphocytic, Chronic, B-Cell 33Carcinoma, Non-Small-Cell Lung 30Recurrence 26Neuroblastoma 25Lymphoma, B-Cell, Marginal Zone 25Central Nervous System Neoplasms 24Ovarian Neoplasms 18Sarcoma 17Brain Neoplasms 17Dendritic Cell Sarcoma, Interdigitating 16Congenital Abnormalities 16Lymphoma, Large-Cell, Anaplastic 15Breast Neoplasms 15Testicular Neoplasms 14Neoplasms, Plasma Cell 14Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 13

Interventions

Etoposide 2olaparib 1ceralasertib 1apatinib 1anlotinib 1Platinum 1Paclitaxel 1Immune Checkpoint Inhibitors 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × SCLC × Etoposide × Clear all
NCT05844150 2025-03-12

A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC

Biotheus Inc.

Phase 2 Active not recruiting
50 enrolled
Thoracic

SCLC

NCT04684017 2020-12-24

Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung Cancer

Shanghai Chest Hospital

Phase 2 Unknown
29 enrolled
Thoracic

SCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡